NCT04492969 is a clinical trial in NSCLC Stage IV, sponsored by Fudan University.

Who is sponsoring NCT04492969?

NCT04492969 is sponsored by Fudan University.

What condition does NCT04492969 study?

NCT04492969 studies NSCLC Stage IV, NSCLC, Recurrent.

Is NCT04492969 still recruiting?

NCT04492969 is currently status unknown. Last updated 31 July 2020.

Last reviewed 2020-07-31 · How we verify

NCT04492969

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Observation of Failure Patterns in NSCLC Treated With ICIs

Status unknown Last updated 31 July 2020

What this trial tests

trial in NSCLC Stage IV in 320 participants. Status unknown.

Timeline

1 September 2020

Primary endpoint
31 August 2023

31 August 2025

Quick facts

Lead sponsor	Fudan University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	320
Start date	1 September 2020
Primary completion	31 August 2023
Estimated completion	31 August 2025
Sites	1 location across China

Conditions studied

NSCLC Stage IV — all drugs for NSCLC Stage IV →
NSCLC, Recurrent — all drugs for NSCLC, Recurrent →

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with NSCLC Stage IV or NSCLC, Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

By prospectively observing the time to the best therapeutic effect of non-small cell lung cancer after ICI treatment, the characteristics of lesion distribution when the best therapeutic effect is reached, and the phenotype of disease progression after ICI treatment response, the investigators intended to explore the failure pattern of NSCLC after the once effective ICI treatment. The investigators also aim to evaluate the feasibility and clinical value of radiotherapy for the treatment of oligo-progressive lesions after ICI.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression.
Prelaj A, Pircher CC, Massa G, Martelli V, et al · · 2021 · cited 15× · PMID 33803958 · DOI 10.3390/cancers13061300
Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.
Xuzhang W, Huang H, Yu Y, Shen L, et al · · 2023 · cited 11× · PMID 36895853 · DOI 10.1177/17588359231156387

Verify or expand the search:

Other recruiting trials for NSCLC Stage IV

Currently open trials in the same condition.

NCT07279402 — TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% · recruiting
NCT06401824 — Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases · Phase 2 · recruiting
NCT06532149 — ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer · recruiting
NCT06313541 — Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunothera · Phase 2 · recruiting
NCT06788366 — AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04492969 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 31 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04492969.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing